This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis Pre-European Charcot Foundation 2025 Course in Baveno, Italy. The expert faculty, Prof. Ludwig Kappos, will review the current clinical trial data and clinical applications of Bruton's Tyrosine Kinase (BTK) inhibitors to manage patients with multiple sclerosis (MS). Prof. Kappos will also discuss the science and emerging clinical trial date for second-generation anti-CD40 therapies. At the conclusion of this lecture, learners will gain better insight into how to treat and manage their patients with multiple sclerosis by utilizing BTK inhibitor therapeutics.
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Review the current clinical trial data and clinical applications of BTK inhibitors to manage patients with MS
Evaluate the science and emerging clinical trial data for second-generation anti-CD40 therapies
I. Clinical Trial Update and Clinical Applications of BTK Inhibitors for MS
II. The Emerging Science of Second-Generation Anti-CD40 Therapies
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Ludwig Kappos, MD | Consultant/Advisor: Bayer AG; Biogen; Bristol-Myers Squibb Company; Celltrion Inc.; Clene Nanomedicine Inc.; EMD Serono; F. Hoffmann-La Roche Ltd; Galapagos NV; Genentech; Immunic Therapeutics; Janssen; Kiniksa Pharmaceuticals; Merck Healthcare AG; Merck & Co., Inc. (MSD); Minoryx Therapeutics; Neurostatus-UHB; Novartis AG; Sanofi; Shionogi B.V.; Wellmera AG; Zai Lab
Grant/Research Support: F. Hoffmann-La Roche Ltd; Innosuisse; Novartis AG |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Sanofi.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606